June 20, 2026 a 01:00 pm
PODD: Analysts Ratings - Insulet Corporation
Insulet Corporation has been demonstrating strong performance in the market with a significant number of "Buy" ratings from analysts. The company's innovative approach to insulin management has secured a solid position in the healthcare sector. Although recent trends indicate minor shifts, the general sentiment towards Insulet remains predominantly positive.
Historical Stock Grades
An analysis of the latest data for Insulet Corporation (PODD) indicates a healthy analyst sentiment, dominated by "Buy" ratings. The most recent figures as of June 2026 show a majority of analysts advocating for a "Buy" with no "Sell" or "Strong Sell" recommendations.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 17 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
- The analyst sentiment towards Insulet has been relatively stable, with "Buy" remaining the dominant recommendation.
- There has been a slight decrease in "Strong Buy" ratings over recent months, indicating cautious optimism.
- No noteworthy increase in "Sell" or "Strong Sell" indicators, suggesting sustained confidence in the stock.
Percentage Trends
- Recent months show a consistency in "Buy" ratings, with fluctuations observed primarily in "Strong Buy" and "Hold".
- "Strong Buy" percentages have decreased slightly, reflecting a more measured sentiment.
- The market appears to maintain a positive outlook towards Insulet, backed by strong product offerings and market position.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-06-12 | Buy | Buy | Truist Securities |
| 2026-05-28 | Neutral | Neutral | Citigroup |
| 2026-05-27 | Outperform | Outperform | RBC Capital |
| 2026-05-27 | Buy | Buy | BTIG |
| 2026-05-18 | Buy | Buy | B of A Securities |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-24 | Neutral | Buy | Rothschild & Co |
| 2026-04-07 | Neutral | Buy | Citigroup |
| 2026-01-12 | Underweight | Equal Weight | Barclays |
| 2025-11-19 | Buy | Neutral | UBS |
| 2025-05-13 | Outperform | Peer Perform | Wolfe Research |
Interpretation
The current analyst sentiment suggests confidence in Insulet Corporation's stock, supported by the high number of "Buy" recommendations. While there have been some downgrades, the absence of "Sell" ratings indicates stable market confidence. Analysts appear to maintain an overall positive outlook with some caution, possibly due to wider market conditions or internal company evaluations.
Conclusion
Insulet Corporation continues to hold a favorable position among analysts, reflecting strong market performance and a robust product lineup. Despite minor shifts towards more conservative ratings, the absence of negative ratings solidifies its standing. This analysis suggests that while the company is on a positive trajectory, investors should remain vigilant of any changes in broader market conditions that might impact sentiment.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years